About: The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China
Creator	Wang, Ke Zhao, Wei Duan, Jun Li, Ji Shu, Weiwei
source	Medline; PMC; WHO
abstract	BACKGROUND: The outbreak of a novel coronavirus (2019-nCoV)-infected pneumonia (NCIP) is currently ongoing in China. Most of the critically ill patients received high-flow nasal cannula (HFNC) oxygen therapy. However, the experience of HFNC in this population is lacking. METHODS: We retrospectively screened 318 confirmed patients with NCIP in two hospitals of Chongqing, China, from January 1st to March 4th, 2020. Among them, 27 (8.4%) patients experienced severe acute respiratory failure including 17 patients (63%) treated with HFNC as first-line therapy, 9 patients (33%) treated with noninvasive ventilation (NIV) and one patient (4%) treated with invasive ventilation. HFNC failure was defined by the need of NIV or intubation as rescue therapy. RESULTS: Of the 17 HFNC patients, 7 (41%) experienced HFNC failure. The HFNC failure rate was 0% (0/6) in patients with PaO(2)/FiO(2) > 200 mm Hg vs. 63% (7/11) in those with PaO(2)/FiO(2) ≤ 200 mm Hg (p = 0.04). Compared with baseline data, the respiratory rate significantly decreased after 1–2 h of HFNC in successful group [median 26 (IQR: 25–29) vs. 23 (22–25), p = 0.03]. However, it did not in the unsuccessful group. After initiation of NIV as rescue therapy among the 7 patients with HFNC failure, PaO(2)/FiO(2) significantly improved after 1–2 h of NIV [median 172 (150–208) mmHg vs. 114 (IQR: 79–130) under HFNC, p = 0.04]. However, two out of seven (29%) patients with NIV as rescue therapy ultimately received intubation. Among the 27 patients with severe acute respiratory failure, four patients were eventually intubated (15%). CONCLUSIONS: Our study indicated that HFNC was the most common ventilation support for patients with NCIP. Patients with lower PaO(2)/FiO(2) were more likely to experience HFNC failure.
has issue date	2020-03-30(xsd:dateTime)
bibo:doi	10.1186/s13613-020-00653-z
bibo:pmid	32232685
has license	cc-by
sha1sum (hex)	ed6e34937c0ad11574f619e32adab283699082c9
schema:url	https://doi.org/10.1186/s13613-020-00653-z
resource representing a document's title	The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China
has PubMed Central identifier	PMC7104710
has PubMed identifier	32232685
schema:publication	Ann Intensive Care
resource representing a document's body	covid:ed6e34937c0ad11574f619e32adab283699082c9#body_text
is schema:about of	named entity 'experience' named entity 'CHINA' named entity 'NASAL CANNULA' named entity 'HIGH' named entity 'POPULATION' named entity 'MOST OF' named entity 'INFECTED' named entity 'OXYGEN THERAPY' named entity 'OUTBREAK' named entity 'PATIENTS' named entity 'PNEUMONIA' named entity 'LACKING' covid:arg/ed6e34937c0ad11574f619e32adab283699082c9 named entity 'ACCESS' named entity 'OPEN' named entity 'NOVEL CORONAVIRUS' named entity 'FLOW' named entity 'ONGOING' named entity 'BACKGROUND' named entity 'CRITICALLY ILL' named entity 'RECEIVED' named entity 'EXPERIENCE' named entity 'CURRENTLY' named entity '2019-nCoV' named entity 'critically ill' named entity 'critically ill patients' named entity 'coronavirus' named entity 'HFNC' named entity 'HFNC' named entity 'HFNC' named entity 'interquartile range' named entity 'China' named entity 'NIV' named entity 'critically ill patients' named entity 'NIV' named entity 'APACHE II' named entity 'oxygen' named entity 'HFNC' named entity 'chest imaging' named entity 'ventilation support' named entity 'intubated' named entity 'NCIP' named entity 'Wuhan' named entity 'NIV' named entity 'critically ill patients' named entity 'rescue therapy' named entity 'pneumonia' named entity 'public health' named entity 'intubation' named entity 'NCIP' named entity 'reverse transcription polymerase chain reaction' named entity 'pneumonia' named entity 'HFNC' named entity 'Respiratory rate' named entity '2019-nCoV' named entity 'acute respiratory failure' named entity 'invasive mechanical ventilation' named entity 'Heart rate' named entity 'intubation' named entity 'retrospective study' named entity 'RT-PCR' named entity 'HFNC' named entity 'HFNC' named entity 'NIV' named entity 'institutional review board' named entity 'HFNC' named entity 'intubation' named entity 'Systolic blood pressure' named entity 'HFNC' named entity 'nasal cannula' named entity 'organ failure' named entity 'pneumonia' named entity 'radiographic' named entity 'HFNC' named entity 'China' named entity 'NCIP' named entity 'Noninvasive ventilation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software